FAQ

lurtotecan liposome

Known as: liposomal lurtotecan, liposome, lurtotecan 
A liposome-encapsulated formulation of lurtotecan with antineoplastic activity. Lurtotecan, a semisynthetic analogue of camptothecin, selectively… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2005
0120012005

Related topics

Related topics

3 relations

Narrower (2)

NX 211OSI 211
lurtotecan

Related mentions per year

Related mentions per year

1998-2016
1990200020102020
lurtotecan liposome
lurtotecan
OSI 211
NX 211

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of…
PURPOSE Liposomal lurtotecan (OSI-211) is a liposomal formulation of the water-soluble topoisomerase I inhibitor lurtotecan… (More)
Is this relevant?
2004
2004
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
OBJECTIVES To determine the safety and efficacy of a novel topoisomerase I inhibitor, liposomal lurtotecan, in patients with… (More)
Is this relevant?
2004
2004
Phase II study of OSI-211 (liposomal lurtotecan) in patients with metastatic or loco-regional recurrent squamous cell carcinoma of the head and neck. An EORTC New Drug Development Group study.
The purpose of this study was to evaluate the activity and safety of OSI-211, the liposomal form of lurtotecan, in patients… (More)
Is this relevant?
2004
2004
A phase 1 study of OSI-211 given as an intravenous infusion days 1, 2, and 3 every three weeks in patients with solid cancers
Purpose: To define the maximum tolerated dose (MTD), recommended phase II dose (RD) and dose limiting toxicity (DLT) of liposomal… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2003
2003
OSI-211, a novel liposomal topoisomerase I inhibitor, is active in SCID mouse models of human AML and ALL.
OSI-211 (liposomal lurtotecan), was evaluated using several different dose schedules (1mg/kg, d1-5, 1.75 mg/kg d1, 3, 5 and 6 mg… (More)
Is this relevant?
2002
2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
PURPOSE To determine the maximum-tolerated and recommended dose, toxicity profile, and pharmacokinetics of the liposomal… (More)
Is this relevant?
2001
2001
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Prolonging tumor exposure to topoisomerase I inhibitors has been correlated to enhance the efficacy of those agents. Lurtotecan… (More)
Is this relevant?